Global

AstraZeneca’s potential $1.5B insitro deal puts AI on the hardest question in cardiometabolic R&D

Ten Years of MS Data Make Delay Harder to Defend

One Blood Test for 50 Cancers Is Closer to the FDA. The Evidence Is Still Fighting Back.

Tirzepatide’s Next Question: What Lies Beyond Cardiovascular Events?

Precision Oncology Has a Scale Problem

The gut microbiome is entering rehabilitation medicine. The evidence is not ready for routine care

One in Eight Cancers Starts With an Infection

Survodutide’s Phase III data raise a bigger question than weight loss

ESR1 Resistance Is Becoming a Treatment Pathway, Not a Footnote
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
